News & Updates
Filter by Specialty:

Meta-analysis: No link between PPI use and gastric cancer
Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.
Meta-analysis: No link between PPI use and gastric cancer
11 Jan 2023
Breast cancer also a male problem
In Malaysia, breast, colorectal, and lung cancers account for approximately half of all reported cancer cases. In order of prevalence, breast cancer tops the list, followed by colorectal, lung, nasopharyngeal, and liver cancers. [Available at https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf Accessed on 27 October 2022]
Breast cancer also a male problem
10 Jan 2023
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
08 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023
Repeat transurethral resection of bladder tumour predicts but does not improve survival
Repeat transurethral resection of bladder tumour prior to radical cystectomy, regardless of whether or not neoadjuvant chemotherapy is administered, does not seem to improve survival in patients with muscle-invasive bladder cancer, reveals a recent study.




